News
TSHA
2.870
-9.46%
-0.300
Taysha Gene Therapies (TSHA) Gets a Buy from Truist Financial
TipRanks · 19h ago
Weekly Report: what happened at TSHA last week (0318-0322)?
Weekly Report · 3d ago
Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease
Gene therapy for a rare neurodegenerative disease called giant axonal neuropathy was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health. The gene therapy shows tolerance and potential therapeutic benefits in 14 children aged 6 to 14. Six of 14 patients regained sensory nerve response after treatment.
Benzinga · 03/21 16:36
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Canaccord Genuity
Dow Jones · 03/21 15:47
Canaccord Genuity Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Benzinga · 03/21 15:37
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Rosenblatt boosted the price target for Micron Technology, Inc. (NASDAQ:MU) from $140 to $225 on Wednesday. TD Cowen raised the pricetarget for Broadcom Inc. From $1,400 to $1.5 million. Needham increased the price targets for Alight and Crocs. Five Below shares gained 1.1%.
Benzinga · 03/21 13:15
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Taysha Gene Therapies, Inc. Shares have a price-to-sales ratio of 35.8x. The company's revenue growth is forecast to decline 60% over the next three years. The stock has seen a 55% gain in the last month and 306% in the past year. The high P/S ratio is in line with the company's industry peers and is a warning sign for investors.
Simply Wall St · 03/21 11:47
Positive Clinical Trials Bolster Buy Rating for Taysha Gene Therapies
TipRanks · 03/21 11:35
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)
TipRanks · 03/21 10:40
Taysha Gene Therapies Price Target Raised to $7.00/Share From $5.00 by Chardan Capital
Dow Jones · 03/21 09:00
Taysha Gene Therapies Is Maintained at Buy by Chardan Capital
Dow Jones · 03/21 09:00
Chardan Capital Maintains Buy on Taysha Gene Therapies, Raises Price Target to $7
Benzinga · 03/21 08:51
Buy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study Catalysts
TipRanks · 03/21 06:38
Taysha Gene Therapies On Edge: The High Stakes of TSHA-102’s Regulatory Approval Journey
TipRanks · 03/21 06:00
Buy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial Health
TipRanks · 03/21 02:25
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. Dipped 31.7% to $4.91 on Wednesday. ETAO International Co., Ltd. Shares shot up 111.5% after the company announced a reverse stock split. NuScale Power Corporation shares tumbled around 35% after spiking 17% on Tuesday.
Benzinga · 03/20 18:03
12 Health Care Stocks Moving In Wednesday's Intraday Session
XTL Biopharmaceuticals shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. Etao International Co (NASDAQ:ETAO) stock rose 84.65% in the session. Annovis Bio (NYSE:ANVS) shares moved up by 39.12%. The company's Q4 earnings report came out yesterday.
Benzinga · 03/20 17:31
Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Taysha Gene Therapies, Inc. Reported positive preliminary results from the phase 1/2 adolescent and adult Rett Syndrome study. The company is using its gene therapy TSHA-102 for the treatment of patients with the rare neurological disorder. Initial data from this study is expected to be released in the 2nd half of 2024.
Seeking Alpha · 03/20 16:30
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Sportradar Group AG shares jumped 10.7% to $11.17 on Wednesday. The company reported better-than-expected fourth-quarter results. Annovis Bio, Inc. Shares surged 25.6% after the company announced a 50-for-1 stock split. The Dow Jones index gained around 0.1% in Wednesday's session.
Benzinga · 03/20 15:41
Taysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disorder
TSHA-102 is an investigational gene therapy for Rett syndrome. Company shares initial clinical data from the first pediatric patient from the REVEAL adolescent and adult trial of TSHA- 102. The company has $143.9 million in cash and cash equivalents.
Benzinga · 03/20 14:22
More
Webull provides a variety of real-time TSHA stock news. You can receive the latest news about Taysha Gene Therapies, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TSHA
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.